In systemic sclerosis, are pulmonary involvement the leading cause of mortality, is Raynaud's phenomenon commonly present, and is skin thickening a characteristic manifestation?

Systemic Sclerosis: Core Clinical Features

All three statements are correct: pulmonary manifestations are indeed the leading cause of death in systemic sclerosis, Raynaud's phenomenon is present in nearly all patients (>95%), and skin thickening is a defining characteristic feature of the disease. 1, 2

a) Pulmonary Manifestations as Leading Cause of Death

Pulmonary involvement is unequivocally the primary cause of mortality in systemic sclerosis, displacing scleroderma renal crisis which was historically the leading cause of death 3. The evidence is clear and consistent:

• Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the main causes of death in SSc 4
• ILD occurs in 40-75% of patients based on lung function changes, with 15-18% experiencing progressive disease 1
• Severe lung disease when diffusion capacity drops below 40% and/or forced vital capacity below 50% contributes significantly to excess morbidity and early mortality 5
• The 5-year survival is approximately 75%, with cardiopulmonary involvement being the primary driver of increased mortality 6

Clinical implication: Screening for ILD and PAH is mandatory in all SSc patients due to the high frequency of these complications and the fact that early intervention can change the natural history 1. This is not optional—it directly impacts survival.

b) Raynaud's Phenomenon Presence

Raynaud's phenomenon is present in nearly all (>95%) patients with systemic sclerosis 1, 2. The evidence is unambiguous:

• Nearly all SSc patients have Raynaud's phenomenon 1
• It often precedes other SSc manifestations by several years 7
• Half of patients with SSc also develop digital ulcers 1

Key distinction: Raynaud's can occur as primary disease (pRP) or SSc-associated (SSc-RP). SSc-RP patients demonstrate:

• Greater cold sensitivity (OR=3.48) 7
• More severe finger pain (OR=3.03) 7
• Lower quality of life (OR=2.69) 7
• Higher association with autoimmune hypothyroidism (OR=3.62) 7

Treatment algorithm per EULAR guidelines 1:

1. First-line: Dihydropyridine calcium channel blockers (especially nifedipine)
2. Second-line: Phosphodiesterase-5 inhibitors OR intravenous iloprost
3. For digital ulcer prevention: Bosentan can reduce development of new digital ulcers

c) Skin Thickening as Characteristic Manifestation

Skin thickening is the defining clinical feature that categorizes SSc subtypes and predicts prognosis 1. The classification is precise:

Disease Subsets Based on Skin Involvement:

Limited cutaneous SSc (lcSSc):

• Skin fibrosis distal to elbows/knees only
• May involve face and neck
• Represents 28.8% of patients 8
• Higher risk for pulmonary arterial hypertension 3

Diffuse cutaneous SSc (dcSSc):

• Skin involvement both distal AND proximal to elbows/knees and/or truncal
• Represents 71.2% of patients 8
• Higher risk for interstitial lung disease 3
• More abrupt onset with constitutional symptoms 9

SSc sine scleroderma:

• 1.5-8% of patients lack definite skin involvement 1
• Still develop major internal organ complications
• Similar trajectory to lcSSc subset

Prognostic Significance:

The modified Rodnan skin score (mRSS) quantifies skin involvement and has direct mortality implications:

• Very high skin scores indicate high risk of mortality 1
• Patients with moderate skin involvement AND worsening ILD are at high mortality risk 1
• Significant correlation exists between mRSS and pulmonary involvement (p<0.05) 8
• Mean mRSS is higher in patients with pulmonary hypertension (28.9±7.62) versus ILD alone (25.7±8.90) 8

Common cutaneous manifestations in order of frequency 8:

• Skin tightening: 88.4%
• Sclerodactyly: 88.4%
• Digital ulcers/pits: 57.7%
• Diffuse edema of hands/feet: 38.4%
• Salt-and-pepper skin: 38.4%
• Calcinosis: 30.8%
• Telangiectasia: 25%
• Contractures: 19.2%

Critical Pitfall:

Do not assume limited skin involvement means limited disease severity. Severe systemic complications including PAH and ILD can manifest regardless of disease duration or subtype 8. Symptoms may not align with disease advancement, making comprehensive evaluation with pulmonary function tests, echocardiography, and HRCT essential for early identification 8.

Treatment for skin fibrosis (early dcSSc only) 1:

• Immunosuppressives: mycophenolate mofetil, methotrexate, cyclophosphamide
• Biologics: rituximab, tocilizumab
• Autologous hematopoietic stem cell transplantation for rapidly progressive disease with high mortality risk

The mRSS serves as a valuable clinical instrument for monitoring disease progression and should be assessed serially 8.